Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway

被引:14
|
作者
Nyga, Mari [1 ,11 ]
Engesaeter, Birgit [1 ]
Castle, Philip E. [2 ,3 ]
Berland, Jannicke Mohr [4 ]
Eide, Maj Liv [5 ]
Iversen, Ole Erik [6 ,7 ]
Jonassen, Christine Monceyron [8 ]
Christiansen, Irene Kraus [9 ]
Vintermyr, Olav Karsten [7 ,10 ]
Trope, Ameli [1 ]
机构
[1] Canc Registry Norway, Oslo, Norway
[2] NCI, Div Canc Prevent, NIH, Rockville, MD USA
[3] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[4] Stavanger Univ Hosp, Stavanger, Rogaland, Norway
[5] Trondheim Reg & Univ Hosp, Trondheim, Norway
[6] Univ Bergen, Inst Clin Sci, Bergen, Norway
[7] Haukeland Hosp, Bergen, Norway
[8] Ostfold Hosp Trust, Ctr Lab Med, Gralum, Norway
[9] Akershus Univ Hosp, Lorenskog, Norway
[10] Univ Bergen, Gades Lab Pathol, Bergen, Norway
[11] Canc Reg istry Norway, Res Dept, Postbox Majorstuen 5313, N-0304 Oslo, Norway
关键词
INTRAEPITHELIAL NEOPLASIA; FOLLOW-UP; CYTOLOGY; RISK; PREVENTION; TRIAGE;
D O I
10.1158/1055-9965.EPI-22-0340
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cervical cancer screening programs are facing a programmatic shift where screening protocol based on human papillomavirus testing (HPV-Screening protocol) is replacing the liquid-based cytology (LBC-Screening protocol). For safe technol-ogy transfer within the nationwide screening programme in Nor-way, HPV-Screening protocol was implemented randomized to compare the real-world effectiveness of HPV-Screening protocol and LBC-Screening protocol at the first screening round. Methods: Among 302,295 women ages 34 to 69 years scheduled to attend screening from February 2015 to June 2017, 157,447 attended. A total of 77,207 were randomly allocated to the HPV-Screening protocol and 80,240 were allocated to the LBC-Screening protocol. All women were followed up for 18 months. Results: The HPV-Screening protocol resulted in a relative increase of 60% in the detection of cervical intraepithelial neoplasia (CIN) grade 2 or worse [risk ratio (RR) = 1.6, 95% confidence interval (CI) = 1.5-1.7], 40% in CIN grade 3 or worse (RR = 1.4, 95% CI = 1.3-1.6), 40% in cancer (RR = 1.4, 95% CI = 1.0-2.1), and 60% in colposcopy referrals (RR = 1.6, 95% CI = 1.5-1.6) compared with LBC-Screening. The perfor-mance of both protocols was age dependent, being more effective in women ages under 50 years. Conclusions: The HPV-Screening protocol was well accepted by women in Norway and detected more CIN2, CIN3, and cancers compared with the LBC-Screening protocol.Impact: A randomized implementation of the HPV-Screening protocol with real-world assessment enabled a gradual, quality assured, and safe technology transition. HPV-based screening protocol may further be improved by using HPV genotyping and age-specific referral algorithms.
引用
收藏
页码:1812 / 1822
页数:11
相关论文
共 50 条
  • [21] Human Papillomavirus Testing for Primary Cervical Cancer Screening Is It Time to Abandon Papanicolaou Testing?
    Feldman, Sarah
    JAMA INTERNAL MEDICINE, 2014, 174 (10) : 1539 - 1540
  • [22] Primary human papillomavirus testing in organized cervical screening
    Dillner, Joakim
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2013, 25 (01) : 11 - 16
  • [23] Primary Human Papillomavirus Testing and Other New Technologies for Cervical Cancer Screening
    Einstein, Mark H.
    Zhou, Nancy
    Gabor, Lisa
    Sahasrabuddhe, Vikrant V.
    OBSTETRICS AND GYNECOLOGY, 2023, 142 (05): : 1036 - 1043
  • [24] Primary Human Papillomavirus Testing and Other New Technologies for Cervical Cancer Screening
    Einstein, Mark H.
    Zhou, Nancy
    Gabor, Lisa
    Sahasrabuddhe, Vikrant V.
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2024, 79 (01) : 28 - 29
  • [25] CERVICOGRAPHY, CYTOLOGY, AND HUMAN PAPILLOMAVIRUS TESTING FOR CERVICAL CANCER SCREENING IN KOREAN WOMEN
    Ki, E.
    Hur, S. Y.
    Bae, S. N.
    Lee, K. H.
    Park, J. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 527 - 528
  • [26] Human papillomavirus testing as a screening tool for cervical cancer
    Koss, LG
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (19): : 2525 - 2525
  • [27] The application of human papillomavirus testing to cervical cancer screening
    Lee, HP
    Seo, SS
    YONSEI MEDICAL JOURNAL, 2002, 43 (06) : 763 - 768
  • [28] Human Papillomavirus DNA Testing for Cervical Cancer Screening
    Belinson, Suzanne E.
    Belinson, Jerome L.
    MOLECULAR DIAGNOSIS & THERAPY, 2010, 14 (04) : 215 - 222
  • [29] Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience
    Agorastos, T
    Dinas, K
    Lloveras, B
    de Sanjose, S
    Kornegay, JR
    Bonti, H
    Bosch, FX
    Constantinidis, T
    Bontis, J
    GYNECOLOGIC ONCOLOGY, 2005, 96 (03) : 714 - 720
  • [30] Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older
    Meijer, Chris J. L. M.
    Berkhof, Johannes
    Castle, Philip E.
    Hesselink, Albertus T.
    Franco, Eduardo L.
    Ronco, Guglielmo
    Arbyn, Marc
    Bosch, F. Xavier
    Cuzick, Jack
    Dillner, Joakim
    Heideman, Danielle A. M.
    Snijders, Peter J. F.
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (03) : 516 - 520